Quantitative Diagnostic System Delivers Results in Minutes at True POC Situation

A unique quantitative diagnostic system could offer a highly effective and affordable alternative to the current costly and time-consuming screening and monitoring systems currently available in the market.

MedMira Inc. (Halifax, Canada) has received a US patent for its new innovative and quantitative test system through which the company aims to expand on its Rapid Vertical Flow Technology (RVF) based diagnostic test and offer a rapid multiplexed quantitative diagnostic system from screening to confirmation to monitoring disease progression. MedMira’s latest novel diagnostic system allows for accessible and efficient diagnostic tools for quantitative results in minutes. The user-friendly interface combined with automated interpretation allows for expansion of the company’s current RVF-based tests and can provide a pathway to significantly increase the technology’s multiplexing abilities. The combination of the RVF and Surface-Enhanced Raman Spectroscopy (SERS) technology creates MedMira’s patented novel high quality and cost-effective tool for the next generation - MIROQ. This enables the amplification of the results produced by its RVF-based rapid tests by creating a unique 3D structure with remarkable reproducibility.

The new addition to MedMira’s patent family creates perfect collaboration to expand its access in both the clinical immunoassay and the Point-of-Care markets, opening new doors into the evolving diagnostic landscape by providing both qualitative and quantitative test results in minutes. The performance and efficiency of this technology has been found to be on par with traditional expensive laboratory testing solutions which are generally limited to high complexity labs. This patented system with the proprietary build-in data capture and analysis software allows for immediate analysis of any positive (reactive) results within one minute. This is in contrast to the current laboratory systems that may take from a couple of hours and up to a week to process samples.

“Our RVF Technology based rapid test provides an immediate quality Yes or No answer enabling health care providers to diagnose specific marker(s) at a true Point-of-Care situation. We strongly believe in the value of such affordable and easy-to-use testing methods, which the world has clearly seen with the COVID-19 pandemic. We are fortunate enough to expand our offering to the market by adding value with the latest success of our technology development – The MIROQ system. MIROQ allows health care providers to receive an immediate diagnosis with both qualitative AND quantitative results and continue disease monitoring in minutes at the most affordable price,” said Hermes Chan, CEO of MedMira Inc. “The synergies of both systems provide the ultimate answer to help people know at the fastest possible time.”

Related Links:
MedMira Inc. 

Visit expo >

New

Gold Member

C-Reactive Protein Reagent

CRP Ultra Wide Range Reagent Kit

Antipsychotic TDM AssaysSaladax Antipsychotic Assays

New

Incubator

HettCube 120

New

Monkeypox Test

Monkeypox Virus Rapid Antibody Test